The Study to Evaluate Efficacy and Safety of MY-REPT Capsule in Primary, Liver Transplantation Recipients (MYLT1)

Open Label, Multicenter, Non-comparative Study to Evaluate the Efficacy and Safety of MY-REPT Capsule in Primary, Liver Transplantation Recipients.

Efficacy and safety of MY-REPT capsule in primary, liver transplantation recipients

Open label, Multicenter, Non-comparative Study to evaluate the efficacy and safety of MY-REPT capsule in primary, liver transplantation

Inclusion Criteria:

• Patient with primary liver transplantation recipients
• Male and Female aged ≥19 and ≤65
• Patient with ABO blood type correspond with Donor's blood type
• Patient who agreement with written informed consent
• Patient who Women if had childbearing potential must have a negative serum or urine pregnancy test at the screening visit and agreement with contraception

Exclusion Criteria:

• Patient with secondary liver transplantation(LT) recipient or other organ transplantation recipient in past or current
• Patient with multi-organ transplantation recipient
• Patient with dual-graft transplantation recipient
• Patient who used body artificial liver before LT
• Cr level >2.0mg/dL in screening
• WBC <2,000/mm3 or ANC <900/mm3 or PLT <30,000/mm3 in screening
• Patient who experienced severe gastrointestinal disorder so investigator judge the man's participation impossible
• Patient who experienced severe infection (need to treatment)
• Patient or Donor with HIV positive
• Patient who need to treat with immunosuppressant or chemistry therapy
• Patient who had taken immunosuppressant within 30days before LT (except to take Corticosteroids and Tacrolimus due to protocol)